MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/art.30128

Медицинская библиотека · Arthritis and rheumatism · 2011

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.

Nigrovic Peter A, Mannion Melissa, Prince Femke H M, Zeft Andrew, Rabinovich C Egla, van Rossum Marion A J, Cortis Elisabetta, Pardeo Manuela, Miettunen Paivi M, Janow Ginger, Birmingham James, Eggebeen Aaron, Janssen Erin, Shulman Andrew I, Son Mary Beth, Hong Sandy, Jones Karla, Ilowite Norman T, Cron Randy Q, Higgins Gloria C

Клиническое исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To examine the safety and efficacy of the interleukin-1 (IL-1) receptor antagonist anakinra as first-line therapy for systemic juvenile idiopathic arthritis (JIA).

METHODS

Patients with systemic JIA receiving anakinra as part of initial disease-modifying antirheumatic drug (DMARD) therapy were identified from 11 centers in 4 countries. Medical records were abstracted using a standardized instrument, and resulting data were analyzed to characterize concomitant therapies, clinical course, adverse events, and predictors of outcome.

RESULTS

Among 46 patients meeting inclusion criteria, anakinra monotherapy was used in 10 patients (22%), while 67% received corticosteroids and 33% received additional DMARDs. Outcomes were evaluated at a median followup interval of 14.5 months. Fever and rash resolved within 1 month in >95% of patients, while C-reactive protein and ferritin normalized within this interval in >80% of patients. Active arthritis persisted at 1 month in 39% of patients, at 3 months in 27%, and at >6 months of followup in 11%. Approximately 60% of patients, including 8 of 10 receiving anakinra monotherapy, attained a complete response without escalation of therapy. Disease characteristics and treatment were similar in partial and complete responders, except that partial responders were markedly younger at onset (median age 5.2 years versus 10.2 years; P = 0.004). Associated adverse events included documented bacterial infection in 2 patients and hepatitis in 1 patient. Tachyphylaxis was not observed.

CONCLUSION

Anakinra as first-line therapy for systemic JIA was associated with rapid resolution of systemic symptoms and prevention of refractory arthritis in almost 90% of patients during the interval examined. These results justify further study of IL-1 inhibition as first-line, rather than rescue, therapy in systemic JIA.

Для цитирования: Nigrovic Peter A, Mannion Melissa, Prince Femke H M, Zeft Andrew, Rabinovich C Egla, van Rossum Marion A J, Cortis Elisabetta, Pardeo Manuela, Miettunen Paivi M, Janow Ginger, Birmingham James, Eggebeen Aaron, Janssen Erin, Shulman Andrew I, Son Mary Beth, Hong Sandy, Jones Karla, Ilowite Norman T, Cron Randy Q, Higgins Gloria C. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.. Arthritis and rheumatism. 2011. DOI: 10.1002/art.30128.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.